Multiple myeloma trials in Greece
39 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.
- Phase 2Taking peopleA Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
- Where
- Alexandroupoli, Athens, Ioannina, Thessaloniki
- Age
- 18 years and over
- People
- 200 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT07227311 · EU 2025-523117-28-00 - Phase 1Taking peopleA study to evaluate the Safety, Pharmacokinetics, and Activity of Subcutaneous Cevostamab (BFCR4350A) in Patients with Relapsed or Refractory Multiple Myeloma (CAMMA 3)
- Where
- Athens
- Age
- 18 years and over
- People
- 45 worldwide
- Run by
- Genentech Inc.
See details and how to join2023-503404-89-00 · EU 2023-503404-89-00 - Phase 3Taking peopleA Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
- Where
- Athens, Ioannina, Thessaloniki
- Age
- 18 years and over
- People
- 893 worldwide
- Run by
- Pfizer
See details and how to joinNCT05020236 · EU 2023-509208-14-00 - Phase 3Taking peopleMagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
- Where
- Alexandroupolis, Athens, Ioannina, Thessaloniki
- Age
- 18 years and over
- People
- 492 worldwide
- Run by
- Pfizer
See details and how to joinNCT06152575 · EU 2023-507871-23-00 - Phase 1/2Taking peopleA Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
- Where
- Athens, Thessaloniki
- Age
- 18 years and over
- People
- 123 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT05714839 · EU 2022-501941-63-00 - Phase 1/2Taking peopleA Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)
- Where
- Athens
- Age
- 18 years and over
- People
- 220 worldwide
- Run by
- Regeneron Pharmaceuticals
See details and how to joinNCT06292780 · EU 2023-507809-34-00 - Phase 2Taking peopleA multi-center, open-label, phase 2 study of Elranatamab in patients with high-risk smoldering multiple myeloma
- Where
- Athens
- Age
- 18 years and over
- People
- 105 worldwide
- Run by
- European Myeloma Network B.V.
See details and how to join2023-505775-70-00 · EU 2023-505775-70-00 - Phase 1/2Taking peopleA Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax (ABBV-453) Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
- Where
- Athens, Chaïdári, Thessaloniki
- Age
- 18 years and over
- People
- 88 worldwide
- Run by
- AbbVie Deutschland GmbH & Co. KG
See details and how to join2025-525105-20-00 · EU 2025-525105-20-00 - No phaseTaking peopleDigital Support for Multiple Myeloma Quality of Life
- Where
- Athens
- People
- 108
- Run by
- CareAcross
See details and how to joinNCT07642362 - Phase 3Taking peopleA Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
- Where
- Alexandroupoli, Athens, Chaïdári, Patras, Thessaloniki
- Age
- 18 years and over
- People
- 520 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT06679101 · EU 2024-516030-35-00 - Phase 3Taking peopleA Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant
- Where
- Alexandroupoli, Athens, Thessaloniki
- Age
- 18 years and over
- People
- 1,000 worldwide
- Run by
- European Myeloma Network B.V.
See details and how to joinNCT06932562 · EU 2024-519827-16-00 - No phaseTaking peopleReal-world Usage of HyQvia in Multiple Myeloma Adults With Secondary Immunodeficiency
- Where
- Athens, Thessaloniki
- Age
- 18 years and over
- People
- 75 worldwide
- Run by
- Takeda
See details and how to joinNCT05879757 - No phaseTaking peopleEuropean Myeloma Network (EMN) Sample Project
- Where
- Athens, Thessaloniki
- Age
- 18 years and over
- People
- 6,000 worldwide
- Run by
- European Myeloma Network B.V.
See details and how to joinNCT06237803 - Phase 2Taking peopleAn Investigator-Initiated, Phase II, Multicenter, Open-Label, Single-Arm, Prospective Clinical Trial to Evaluate the Efficacy and Safety of Alternating Bortezomib-Based Regimens in Combination With DaratUMumab Followed by Maintenance With Daratumumab in the Frontline Setting of Primary Plasma CEll L
- Where
- Alexandroupoli, Athens, Piraeus, Thessaloniki
- Age
- 18 years to 80 years
- People
- 43
- Run by
- Hellenic Society of Hematology
See details and how to joinNCT06636552